571189-16-7

基本信息
4-(6-硝基-3-吡啶基)-1
1-BOC-4-(6-硝基-3-吡啶基)哌嗪
4-(6-硝基吡啶-3-基)哌嗪-1-羧酸叔丁酯
4-(6-硝基-3-吡啶基)-1-哌嗪甲酸叔丁酯
1-BOC-4-(6-NITROPYRIDIN-3-YL)PIPERAZINE
4-(6-Nitropyridin-3-yl)piperazine, N1-Boc protected
4-(6-Nitropyridin-3-yl)piperazine, N1-BOC protected 97%
tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
Tert. butyl-4-(6-Nitropyridin-3-yl)piperazino-1-carboxylate
4-(6-nitropyridin-3-yl)-1-piperazinecarboxylic acid tert-butyl ester
4-(6-Nitropyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester
4-(6-Nitro-3-pyridinyl)-1-piperazinecarboxylic acid tert-butyl ester
NaMe:4-(6-Nitro-3-pyridinyl)-1-piperazinecarboxylic acid tert-butyl ester
物理化学性质
制备方法

775288-71-6

24424-99-5

571189-16-7
在氮气保护下,将1-(6-硝基吡啶-3-基)哌嗪(15.6 g,0.075 mol)悬浮于120 mL四氢呋喃(THF)中。依次加入三乙胺(10.5 mL,0.075 mol)和4-二甲基氨基吡啶(0.46 g,5 mol%)至悬浮液中。将二碳酸二叔丁酯(16.6 g,0.075 mol)溶解于50 mL THF中,转移至滴液漏斗中。缓慢滴加该溶液至搅拌的悬浮液中,控制滴加速度使反应温度维持在27°C以下。滴加完毕后,将反应混合物冷却至室温,随后加热至回流。回流反应1小时后,过滤除去少量不溶物。减压浓缩除去溶剂,将黄色残余物在乙酸乙酯(EtOAc)和水之间分配。水相用EtOAc萃取两次。合并有机层,依次用少量水和饱和氯化钠溶液洗涤,干燥后减压浓缩。所得固体通过2-丙醇(经活性炭处理)重结晶,得到目标产物4-(6-硝基-3-吡啶基)-1-哌嗪甲酸叔丁酯,约19 g(产率约80%)。核磁共振氢谱(1H NMR,CDCl3)δ: 1.49(s,9H),3.46(m,4H),3.65(m,4H),7.20(m,1H),8.17(m,2H)。质谱(m/z): 309。
参考文献:
[1] Patent: WO2006/95159, 2006, A1. Location in patent: Page/Page column 77-78
[2] British Journal of Pharmacology, 2018, vol. 175, # 12, p. 2399 - 2413
[3] Journal of Medicinal Chemistry, 2005, vol. 48, # 7, p. 2388 - 2406
[4] Patent: WO2006/8545, 2006, A2. Location in patent: Page/Page column 153
[5] Journal of Medicinal Chemistry, 2010, vol. 53, # 22, p. 7938 - 7957
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/05/22 | H54465 | 1-Boc-4-(6-硝基-3-吡啶基)哌嗪, 97% 1-Boc-4-(6-nitro-3-pyridyl)piperazine, 97% | 571189-16-7 | 1g | 1085元 |
2025/05/22 | H54465 | 1-Boc-4-(6-硝基-3-吡啶基)哌嗪, 97% 1-Boc-4-(6-nitro-3-pyridyl)piperazine, 97% | 571189-16-7 | 5g | 5292元 |
2025/05/22 | XW0257118916703 | 4-(6-硝基-3-吡啶基)-1-哌嗪甲酸叔丁酯 | 571189-16-7 | 10G | 107元 |